Regeneron Pasatru (garetosmab-grts) Shows Zero New HO Lesions in Adult FOP Patients in OPTIMA Extension
Regeneron Pasatru (garetosmab-grts) showed no new heterotopic ossification lesions from week 56 to week 84 in adults with FOP. The OPTIMA extension data were presented at ASBMR on October 12, 2026.
